Movement Alert｜WUXI XDC Intraday Rise 3.63% in Regular Trading, ADC and CXO Sentiment Lifts the Sector

Market Focus10-20

On October 20, WUXI XDC recorded an Intraday Rise of 3.63% in Regular Trading, trading at HK$77.05, with turnover of HK$150 million.

The move aligned with renewed strength across the ADC and CXO chain. Market attention returned to ADC outsourcing names after a major new ADC strategic cooperation deal involving Hansoh Pharma and Roche supported sector sentiment, while institutions recently continued to favor innovative drug developers and leading CXO names.

Background indicators were supportive. WUXI XDC operates in the ADC CRDMO segment, where demand expectations remain firm. In the first half, the company reported revenue of RMB3.701 billion, up 37.0% year over year, and adjusted net profit of RMB1.027 billion, up 37.4%, with adjusted net margin at 27.8%. Broader industry data also showed Hong Kong-listed and A-share CXO revenue growth of 29.2% and 25.3%, respectively, reinforcing expectations for leading companies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment